ImmuPharma PLC (LSE:IMM), a leading specialist in peptide based drug discovery and development, announces a significant milestone in evidencing the unique mechanism of action (“MOA”) of its P140 autoimmune technology platform.
Importantly, these new discoveries announced today, in respect to the MOA of P140, highlight that:
· P140 has a unique MOA: The results provide direct evidence for the first time of a major key hypothesis of the unique MOA of P140.
· P140 is non-immunosuppressive: Unlike the most advanced therapies currently available for the treatment of autoimmune diseases, these findings indicate that P140 does not reduce or block the body’s ability to mount a specific immune response.
· P140 is effective and safe: These findings confirm P140’s potential as a safe and effective treatment for patients suffering from systemic lupus erythematosus (SLE).
These discoveries result from a new preclinical study designed by ImmuPharma Biotech’s team and conducted at a world leading Laboratory in the USA. While detailed data will be released in due course, these findings allow ImmuPharma to further expand its intellectual property portfolio, with additional new patents, strengthening the commercial viability of the P140 technology platform.
Relevant therapy markets in this area are forecast to reach global sales of c.$360 billion by 2030. There have been 11 relevant therapy product licensing deals averaging $1bn total deal value in last 2 years. (UBS Investment Banking Reports).
Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said:
“These stunning results clearly demonstrate the unique MOA of P140 and this data adds significantly to our ongoing discussions with potential partners and our objective to secure the optimum deal(s) for our shareholders.”
Commenting on this announcement, Sébastien Goudreau, CEO of ImmuPharma Biotech, said:
“These results are extremely compelling. Not only do they validate our MOA, they also indicate that P140 has the possibility to become a central treatment for a number of autoimmune diseases. Patients can be very hopeful, I certainly am!”
|
For further information please contact:
|
